Site icon pharmaceutical daily

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 21, 13, 1, 31 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to buy

Key Topics Covered:

  1. Introduction
  2. Non Alcoholic Fatty Liver Disease (NAFLD) – Overview
  3. Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development
  4. Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment
  5. Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development
  6. Non Alcoholic Fatty Liver Disease (NAFLD) – Drug Profiles
  7. Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects
  8. Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products
  9. Non Alcoholic Fatty Liver Disease (NAFLD) – Product Development Milestones
  10. Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m7zzzx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Liver and Kidney Disorders Drugs

Exit mobile version